Cocaine abuse is common among schizophrenics. In fact, the Epidemiological Catchment Area study found that 16.7% of cocaine addicts had a comorbid diagnosis of schizophrenia (odds ration of 13), and 47% of schizophrenics have a lifetime substance use disorder. These individuals respond poorly to traditional drug abuse and psychiatric treatments. There exists a great clinical and research need to develop innovative and well defined psychopharmacological treatments for this population which address both the psychiatric and substance abuse problems. This grant application proposes to evaluate pharmacotherapies for schizophrenic cocaine abusers and proposes to begin with a 12 week double blind trial comparing adjunctive mazindol versus placebo. All patients will be maintained on neuroleptic medication for schizophrenia. Also, patients will be randomized to either a day hospital (25 hours / week) or an intensive outpatient program (12 hours / week). Both of these dual diagnosis programs emphasize group therapy, but include individual case management and family participation. The core psychotherapy approach for the program is Dual Diagnosis Relapse Prevention (DDRP) which consists of modified substance abuse relapse prevention and psychiatric social skills training (psychiatric symptom and medication management). After the 12 week clinical trial, patients will be re-evaluated at three and six month follow-up sessions.
The specific aims of this grant proposal are to: 1. Determine the efficacy of adjunctive mazindol in improving substance abuse treatment outcomes in schizophrenic cocaine abusers. 2. Compare the relative efficacy of the two levels of psychosocial treatment (including cost-effectiveness). 3. Stratify by gender and assess differences in treatment outcome. 4. Assess predictors of treatment efficacy including severity of cocaine usage, negative symptoms of schizophrenia and depression.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009250-05
Application #
6104092
Study Section
Project Start
1998-09-30
Project End
1999-09-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12
Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7
Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25
Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27
Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71
Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51
Stine, S M; Grillon, C G; Morgan 3rd, C A et al. (2001) Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berl) 154:274-81
Jacobsen, L K; Southwick, S M; Kosten, T R (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-90
Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5

Showing the most recent 10 out of 39 publications